Share on StockTwits

Alcobra (NASDAQ:ADHD) released its earnings data on Monday. The company reported ($0.57) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.57), AmericanBankingNews.com reports.

Alcobra (NASDAQ:ADHD) opened at 19.95 on Monday. Alcobra has a 52-week low of $11.49 and a 52-week high of $26.96. The stock’s 50-day moving average is $18.26 and its 200-day moving average is $18.95. The company’s market cap is $272.0 million.

A number of research firms have recently commented on ADHD. Analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday, August 4th. They set an “overweight” rating and a $42.00 price target on the stock. On a related note, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock. Finally, analysts at WBB Securities initiated coverage on shares of Alcobra in a research note on Thursday, June 26th. They set a “hold” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Alcobra presently has a consensus rating of “Buy” and a consensus target price of $33.83.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.

Receive News & Ratings for Alcobra Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.